We propose that treating Kras-driven NSCLC by applying GSK126 in a neoadjuvant-like manner enhances the tumor’s susceptibility to subsequent treatments that can be defined experimentally. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.